Upstream Bio (UPB) Other Accumulated Expenses (2024 - 2025)
Upstream Bio (UPB) posted quarterly Other Accumulated Expenses of $55000.0 for Q3 2025, down 53.39% year-over-year from $118000.0 in Q3 2024, and down 53.39% quarter-over-quarter from $118000.0 in Q3 2024.
Powered by 
Analysis
Upstream Bio (UPB) Other Accumulated Expenses (2024 - 2025) Analysis & Trends
Upstream Bio's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $55000.0 for Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Upstream Bio | 327.95 Mn | 327.95 Mn | -3.29 Mn |